#ELAN↓

ELAN/ 12/09/2025 · 9:01 AM

Barclays Starts Coverage on Elanco With Overweight Rating

Barclays initiates coverage on Elanco with an Overweight rating and $30 target, highlighting improving sentiment in specialty pharmaceuticals and shifting focus toward innovation, margins, and lower debt.

ELAN/ 11/21/2025 · 2:50 PM

FDA Grants Historic EUA for Elanco's Credelio CAT

The FDA issued an emergency authorization for Credelio CAT (lotilaner) to treat dangerous New World Screwworm (NWS) in cats, preparing the U.S. for this emerging health threat.